Search Within

Chrisann Kyi Kyi

  1. "Journal for ImmunoTherapy of Cancer"
Formats
  1. Journal Article (3)
  2. Meeting Abstract (1)
Groups
  1. Department of Medicine (4)
  2. GDMT, Medicine (4)
  3. Gynecologic Medicine Service (4)
  4. Gynecology Disease Management Team (4)
  5. Solid Tumor Oncology Division (4)
  6. Biostatistics Service (1)

More Groups

People
  1. Alexia Iasonos (1)
  2. Carol Aghajanian (1)
  3. Ekaterina Doubrovina (1)
  4. Paul Sabbatini (1)
  5. Qin Zhou (1)
  6. Richard O'Reilly (1)

More People

Years
  1. 2022 (1)
  2. 2021 (2)
  3. 2020 (1)
Publications
  1. Journal for ImmunoTherapy of Cancer (4)
Publishers
  1. Biomed Central Ltd (4)

Results (4)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies
    Journal Article

    Schöffski, P.; Tan, D. S. W.; Martín, M.; Ochoa-de-Olza, M.; Sarantopoulos, J.; Carvajal, R. D.; Kyi, C.; Esaki, T.; Prawira, A.; Akerley, W.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer
    Journal Article

    Kyi, C.; Doubrovina, E.; Zhou, Q.; Kravetz, S.; Iasonos, A.; Aghajanian, C.; Sabbatini, P.; Spriggs, D.; O'Reilly, R. J.; O'Cearbhaill, R. E.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
    Journal Article

    Ferris, R. L.; Spanos, W. C.; Leidner, R.; Gonçalves, A.; Martens, U. M.; Kyi, C.; Sharfman, W.; Chung, C. H.; Devriese, L. A.; Gauthier, H.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • A phase II, multicenter study of the safety and efficacy of LAG525 in combination with spartalizumab in patients with advanced malignancies
    Meeting Abstract

    Lin, C. C.; Garralda, E.; Schoffski, P.; Hong, D.; Siu, L.; Martin, M.; Maur, M.; Hui, R.; Soo, R.; Chiu, J.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save